Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of January 2026, with the report dated January 9, 2026. The filing discloses a corporate action regarding the extension of an existing equity distribution agreement rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of an equity distribution agreement amendment.
Material Changes
On January 8, 2026, the Company entered into the First Amendment to its Equity Distribution Agreement with Maxim Group LLC. The material change involves extending the termination date of the agreement from January 13, 2026, to March 13, 2026. Under the amended agreement, the Company may continue to offer and sell up to $13,960,500 of its ordinary shares through the Sales Agent.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are detailed in this report, other than the standard incorporation of the amendment into existing registration statements (Forms F-3 and S-8).
Investor Verification Checklist
- Verify the exact remaining share count available for sale under the $13,960,500 cap.
- Confirm the new termination date of March 13, 2026, for the Equity Distribution Agreement.
- Review the full text of Exhibit 10.1 for any changes to commission rates or sales procedures not summarized here.
- Check subsequent filings for any actual share sales executed under this extended agreement.